Hypoxia-Preconditioned Human Umbilical Cord Mesenchymal Stem Cells Transplantation Ameliorates Inflammation and Bone Regeneration in Peri-Implantitis Rat Model

Abstract

Objective The failure of dental implant treatments is predominantly attributed to peri-implantitis, which entails chronic inflammation within the peri-implant tissue, ultimately leading to tissue degradation. Addressing this condition, human umbilical cord mesenchymal stem cell (hUCMSC) transplantation serves as a regenerative therapy; however, concerns regarding the viability and efficacy of transplanted cells in inflamed regions persist. Hypoxic preconditioning of hUCMSCs has emerged as a potential strategy for augmenting their regenerative and immunomodulatory capacities. This study aimed to evaluate the expression of inflammatory (tumor necrosis factor [TNF]-α) and bone regenerative biomarkers (nuclear factor of activated T-cell [NFATc1], osteocalcin, collagen type I alpha 1 [COL1α1]) within peri-implantitis models subsequent to the transplantation of hypoxia-preconditioned hUCMSCs.

Materials and Methods Peri-implantitis models were established through the insertion of implants into the femur bone of 42 Wistar strain Rattus norvegicus, followed by intrasocket injection of lipopolysaccharide. The experimental animals were categorized into three groups (control, normoxia, and hypoxia) and underwent observation on days 14 and 28. The expression levels of TNF-α, NFATc1, COL1α1, and osteocalcin were evaluated using immunohistochemical staining, and the resulting data were subjected to one-way analysis of variance analysis (p < 0.05).

Results Transplantation of hypoxia-preconditioned hUCMSCs significantly ameliorated inflammation and osteoclastogenesis, as evidenced by significant reductions in TNF-α and NFATc1 expression compared with the control group. Furthermore, hypoxic preconditioning of hUCMSCs demonstrated a significant elevation in the expression of osteocalcin and COL1α1 relative to the control group.

Conclusion The transplantation of hypoxia-preconditioned hUCMSCs exhibited a capacity to ameliorate inflammation and enhance bone regenerative processes in peri-implantitis rat models.

Keywords

dental implant - mesenchymal stem cell - peri-implantitis - bone regeneration - rat model - medicine

Publikationsverlauf

Artikel online veröffentlicht:
07. November 2024

• References

• 1 Rokaya D, Srimaneepong V, Wisitrasameewon W, Humagain M, Thunyakitpisal P. Peri-implantitis update: risk indicators, diagnosis, and treatment. Eur J Dent 2020; 14 (04) 672-682
• 2 Kuntjoro M, Prasetyo EP, Cahyani F. et al. Lipopolysaccharide's cytotoxicity on human umbilical cord mesenchymal stem cells. Pesqui Bras Odontopediatria Clin Integr 2020; 20: e0048
• 3 Prasetyo EP, Juniarti DE, Sampoerno G. et al. The antibacterial efficacy of calcium hydroxide-iodophors and calcium hydroxide-barium sulfate root canal dressings on Enterococcus faecalis and Porphyromonas gingivalis in vitro. Dent J 2022; 55 (02) 62-66
• 4 Prasetyo EP, Sampoerno G, Juniarti DE. et al. Effect of lipopolysaccharide-induced apical periodontitis in diabetes mellitus rats on periapical inflammation. Eur J Dent 2023; 17 (04) 1146-1152
• 5 Fragkioudakis I, Tseleki G, Doufexi AE, Sakellari D. Current concepts on the pathogenesis of peri-implantitis: a narrative review. Eur J Dent 2021; 15 (02) 379-387
• 6 Prasetyo EP, Widjiastuti I, Cahyani F. et al. Cytotoxicity of calcium hydroxide on human umbilical cord mesenchymal stem cells. Pesqui Bras Odontopediatria Clin Integr 2020; 20: e0044
• 7 Prasetyo EP, Kuntjoro M, Goenharto S. et al. Calcium hydroxide increases human umbilical cord mesenchymal stem cells expressions of apoptotic protease-activating factor-1, caspase-3 and caspase-9. Clin Cosmet Investig Dent 2021; 13: 59-65
• 8 Xie Q, Liu R, Jiang J. et al. What is the impact of human umbilical cord mesenchymal stem cell transplantation on clinical treatment?. Stem Cell Res Ther 2020; 11 (01) 519
• 9 Ariestania V, Hendrijantini N, Prahasanti C. et al. Cytotoxicity of HA-TCP scaffold on human umbilical cord mesenchymal stem cells using MTT assay. Int J Integ Eng 2022; 14 (02) 80-85
• 10 Hendrijantini N, Kusumaningsih T, Rostiny R, Mulawardhana P, Danudiningrat CP, Rantam FA. A potential therapy of human umbilical cord mesenchymal stem cells for bone regeneration on osteoporotic mandibular bone. Eur J Dent 2018; 12 (03) 358-362
• 11 Kuntjoro M, Hendrijantini N, Prasetyo EP. et al. Human umbilical cord mesenchymal stem cells accelerate and increase implant osseointegration in diabetic rats. J Appl Oral Sci 2023; 31: e20220375
• 12 Kuntjoro M, Agustono B, Prasetyo EP, Salim S, Rantam FA, Hendrijantini N. The effect of advanced glycation end products (AGEs) on human umbilical cord mesenchymal stem cells (hUCMSCs) with regard to osteogenesis and calcification. Res J Pharm Tech 2021; 14 (08) 4019-4024
• 13 Kuntjoro M, Hendrijantini N, Prasetyo EP. et al. Cobalt chloride as a hypoxia mimicking agent induced HIF-1a and mTOR expressions of human umbilical cord mesenchymal stem cells. Pesqui Bras Odontopediatria Clin Integr 2024; 24: e220128
• 14 Nugraha AP, Prasetyo EP, Kuntjoro M. et al. The effect of cobalt (II) chloride in the viability percentage and the induced hypoxia inducible factor-1a of human adipose mesenchymal stem cells (hAMSCs): an in vitro study. Syst Rev Pharm 2020; 11 (06) 308-314
• 15 Nugraha AP, Ihsan IS, Dinaryanti A. et al. Cobalt (II) chloride in enhancing hypoxia inducible factor-1a expression of gingival derived mesenchymal stem cells in vitro. Res J Pharm Technol 2021; 14 (05) 2639-2642
• 16 Pulido-Escribano V, Torrecillas-Baena B, Camacho-Cardenosa M, Dorado G, Gálvez-Moreno MÁ, Casado-Díaz A. Role of hypoxia preconditioning in therapeutic potential of mesenchymal stem-cell-derived extracellular vesicles. World J Stem Cells 2022; 14 (07) 453-472
• 17 Heitz-Mayfield LJA. Peri-implant mucositis and peri-implantitis: key features and differences. Br Dent J 2024; 236 (10) 791-794
• 18 Oliveira JA, de Oliveira Alves R, Nascimento IM, Hidalgo MAR, Scarel-Caminaga RM, Cristina Pigossi S. Pro- and anti-inflammatory cytokines and osteoclastogenesis-related factors in peri-implant diseases: systematic review and meta-analysis. BMC Oral Health 2023; 23 (01) 420
• 19 Gauthier AE, Rotjan RD, Kagan JC. Lipopolysaccharide detection by the innate immune system may be an uncommon defence strategy used in nature. Open Biol 2022; 12 (10) 220146
• 20 Li L, Park YR, Shrestha SK, Cho HK, Soh Y. Suppression of inflammation, osteoclastogenesis and bone loss by PZRAS extract. J Microbiol Biotechnol 2020; 30 (10) 1543-1551
• 21 Ayala-Cuellar AP, Kang JH, Jeung EB, Choi KC. Roles of mesenchymal stem cells in tissue regeneration and immunomodulation. Biomol Ther (Seoul) 2019; 27 (01) 25-33
• 22 Liu P, An Y, Zhu T. et al. Mesenchymal stem cells: emerging concepts and recent advances in their roles in organismal homeostasis and therapy. Front Cell Infect Microbiol 2023; 13: 1131218
• 23 Wicaksono S, Nugraha AP, Rahmahani J. et al. Adipose mesenchymal stem cell metabolites oral gel enhance pro-angiogenic factors expression, angiogenesis, and clinical outcome of oral ulcer rat model. Eur J Dent 2024; 18 (01) 117-123
• 24 Fan XL, Zhang Y, Li X, Fu QL. Mechanisms underlying the protective effects of mesenchymal stem cell-based therapy. Cell Mol Life Sci 2020; 77 (14) 2771-2794
• 25 Kuntjoro M, Hendrijantini N, Prasetyo EP. et al. Cobalt chloride as a hypoxia mimicking agent induced HIF-1αand mTOR expressions of human umbilical cord mesenchymal stem cells. Pesquisa Brazileira em Odontopediatria e Clinica Integrada 2024; 24: 1-10
• 26 Ma M. Role of hypoxia in mesenchymal stem cells from dental pulp: influence, mechanism and application. Cell Biochem Biophys 2024; 82 (02) 535-547
• 27 Liu J, Gao J, Liang Z. et al. Mesenchymal stem cells and their microenvironment. Stem Cell Res Ther 2022; 13 (01) 429
• 28 Lee HJ, Jung YH, Choi GE, Kim JS, Chae CW, Han HJ. Role of HIF1α regulatory factors in stem cells. Int J Stem Cells 2019; 12 (01) 8-20
• 29 Yusoff FM, Nakashima A, Kawano KI. et al. Implantation of hypoxia-induced mesenchymal stem cell advances therapeutic angiogenesis. Stem Cells Int 2022; 2022: 6795274
• 30 Li H, Ji XQ, Zhang SM, Bi RH. Hypoxia and inflammatory factor preconditioning enhances the immunosuppressive properties of human umbilical cord mesenchymal stem cells. World J Stem Cells 2023; 15 (11) 999-1016
• 31 Saremi L, Shafizadeh M, Esmaeilzadeh E. et al. Assessment of IL-10, IL-1ß and TNF-α gene polymorphisms in patients with peri-implantitis and healthy controls. Mol Biol Rep 2021; 48 (03) 2285-2290
• 32 Gundogar H, Uzunkaya M. The effect of periodontal and peri implanter health on IL-1β and TNF-α levels in gingival crevicular and peri implanter sulcus fluid: a cross sectional study. Odovtos Int J Dent Sci 2020; 23 (01) 168-177
• 33 Nugraha AP, Ramadhani NF, Riawan W. et al. Gingival mesenchymal stem cells metabolite decreasing TRAP, NFATc1, and sclerostin expression in LPS-associated inflammatory osteolysis in vivo. Eur J Dent 2023; 17 (03) 881-888
• 34 Lin X, Patil S, Gao YG, Qian A. The bone extracellular matrix in bone formation and regeneration. Front Pharmacol 2020; 11: 757
• 35 Koblenzer M, Weiler M, Fragoulis A, Rütten S, Pufe T, Jahr H. Physiological mineralization during in vitro osteogenesis in a biomimetic spheroid culture model. Cells 2022; 11 (17) 2702
• 36 Hendrijantini N, Hartono P, Ari MDA, Rantan FA. Human umbilical cord mesenchymal stem-cell therapy to increase the density of osteoporotic mandibular bone. Eur J Dent 2019; 13 (01) 58-63
• 37 Carvalho MS, Silva JC, Hoff CM. et al. Loss and rescue of osteocalcin and osteopontin modulate osteogenic and angiogenic features of mesenchymal stem/stromal cells. J Cell Physiol 2020; 235 (10) 7496-7515
• 38 Nugraha AP, Narmada IB, Winoto ER. et al. Gingiva mesenchymal stem cells normoxic or hypoxic preconditioned application under orthodontic mechanical force on osterix, osteopontin, and ALP expression. Eur J Dent 2024; 18 (02) 501-509
• 39 Lastianny SP, Sukmawati AN, Soesilowati ASK. Immunohistochemistry assay of osteocalcin on bone healing with CHA-10% propolis. J Dentomaxillofac Sci 2022; 7 (02) 97-101